H. Fischer Seth - Aug 26, 2024 Form 4 Insider Report for AGILE THERAPEUTICS INC (AGRX)

Role
Director
Signature
/s/ Geoffrey P. Gilmore, Attorney-in-fact
Stock symbol
AGRX
Transactions as of
Aug 26, 2024
Transactions value $
-$1,484
Form type
4
Date filed
8/26/2024, 05:32 PM
Previous filing
Jun 20, 2024
Next filing
Aug 29, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGRX Common Stock Disposed to Issuer -$1.48K -976 -100% $1.52 0 Aug 26, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

H. Fischer Seth is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 976 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,484, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person